Rucaparib Maintenance Therapy in Advanced Cervical Cancer
Status:
Withdrawn
Trial end date:
2019-10-10
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of PARP inhibitor, rucaparib as maintenance therapy for locally
advanced cervical cancer
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society for Gynaecologic Oncology Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
Belgian Gynaecological Oncology Group Central and Eastern European Oncology Group GCP-enhederne GSO Global Clinical Research BV Institute of Cancer Research, United Kingdom North Eastern German Society of Gynaecological Oncology North Eastern Germany Society of Gynaecologic Oncology PGOG (Polish Gynaecologic Oncology Group) Princess Margaret Hospital, Canada